NHEJ 抑制剂– SCR7

英文名 ：Viewsolid

供应商 ：北京唯尚立德

NHEJ 抑制剂– SCR7(Catalog. No. C007)
学名: 5,6-bis((E)-benzylideneamino)-2-mercaptopyrimidin-4-ol

Cat. NO	C007
分子量	334.39
分子式	C18H14N4OS
纯度	≥ 98%
CAS#	1533426-72-0
溶剂	DMSO
浓度	50mM
储存条件	DMSO: 4℃ 3 month -20℃ 1year -80℃ for longterm

生物活性：
SCR7 is a potent and selective inhibitor of non-homologous end joining (NHEJ). It inhibits joining of DSBs in cell-free DNA repair system, blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I, thereby leading to accumulation of DSBs within the cells, culminating into cytotoxicity. SCR7 inhibits NHEJ in a Ligase IV-dependent manner within cells, and activates the intrinsic apoptotic pathway. More importantly, SCR7 impedes tumor progression in mouse models, and when co-administered with DSB-inducing therapeutic modalities it enhances their sensitivity significantly. SCR7 to target NHEJ offers a novel strategy toward the treatment of cancer and improvement of existing regimens.

参考文献：
1. Srivastava M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. (2012) Cell. 151(7):1474-87.
2. Takeshi Maruyama, et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. (2015) Nature Biotechnology. 33:538-542.
Products are for research use only. Not for human use.